Immunity and Cancer - IRCM - Montpellier
- BONNEFOY Nathalie
Research axis :
Expertise / know-how:
Tumors have been recognized as more complex and heterogeneous than previously thought with evidences that tumor microenvironment significantly contributes to cancer development. Research programs developed in our group aim at a better understanding of the relationships between cancer and the immune system, with a specific interest for
- the role of mediators of inflammation in cancer development, and
- the contribution of immune effectors to cancer prevention or treatment, with a special focus to the modulation of tumor immunity by therapeutic monoclonal antibodies.
We are developing:
- In vitro assays dedicated to the analysis of effectors of the anti-tumor immune response.
- In vivo preclinical tumor models (syngenic and xenograft tumor models).
- Treatments with chemo-, radio-, and immunotherapies.
- Analysis of tumor immune microenvironment by multi-parametric flow cytometry.
Institut de Recherche en Cancérologie de Montpellier, INSERM U1194